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Abstract
Background: Sweat gland adenocarcinoma is a rare malignancy with high metastatic potential seen
more commonly in later years of life. Scalp is the most common site of occurrence and it usually
spreads to lymph nodes. Liver, lung and bones are the distant sites of metastasis with fatal results.
The differentiation between apocrine and eccrine metastatic sweat gland carcinoma is often
difficult. The criteria's are inadequate to be of any practical utility.
Case Report: Two cases of metastatic sweat gland adenocarcinoma (one of eccrine and the other
one of apocrine origin) are being reported on account of the rarity and different outcome.
Conclusion: Sweat gland carcinomas are rare cancers with a poor prognosis often presenting as
histological surprises. Surgery in the form of wide local excision and lymph node dissection is the
mainstay of treatment. Chemotherapy and/or radiotherapy has limited role.
Introduction
Sweat gland neoplasms (microcystic adenexal carcinoma)
are rare with approximately 200 cases of eccrine sweat
gland and 38 cases of apocrine gland carcinoma being
reported in the world literature [1,2]. It is often not diag-
nosed clinically or incorrectly and is encountered as a his-
tological surprise i.e. as an incidental finding at histology
of resected specimen. A wide surgical excision is the treat-
ment of choice with clearance of draining lymph nodes.
The role of adjuvant chemotherapy and radiotherapy is
not established. We report here two cases of sweat gland
adenocarcinoma one each of eccrine and apocrine origin.
Case Report
Case 1
A 45-year-old man presented to the surgical wing with
swelling in the right axilla of 2 months duration. There
was a past history of pulmonary tuberculosis, two years
back, for which patient had taken anti tubercular treat-
ment. On examination the thyroid, breasts, chest, abdo-
men, and per rectal examinations were normal.
Examination of axilla revealed a tiny, indurated, non ten-
der, pink skin nodule of about 5 mm diameter (figure 1)
with multiple, firm, non tender, discrete, axillary lymph
nodes measuring 1 to 4 cm.
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Hematological and biochemical investigations were
within normal limits. Chest roentgenogram showed
healed tubercular lesion in right apical area. A contrast
enhanced computerized tomographic scan (CECT) of the
chest and fiber optic bronchoscopy was carried out which
did not reveal any significant pathology except healed
fibro cavitatory lesion in the right apex. Ultrasound exam-
ination of both the breasts, and abdomen was essentially
normal. Fine needle aspiration cytology (FNAC) from the
axillary lymph node revealed metastatic adenocarcinoma.
Excision biopsy of the lymph node and suspected primary
skin lesion was performed which revealed metastatic
sweat gland adenocarcinoma with solid and glandular
pattern (figure 2). The tumor cells were Periodic Acid
Schiff (PAS) positive, diastase sensitive and were estrogen
receptor negative. A diagnosis of sweat gland adenocarci-
noma, probably of eccrine origin was made. An axillary
lymph node dissection along with excision of the previous
scar was carried out. While raising the upper skin flap two-
satellite cutaneous nodules each measuring, 2–3 mm in
diameter, were found and were excised en bloc. Histologi-
cal examination of the resected specimen confirmed the
diagnosis of metastatic sweat gland adenocarcinoma of
eccrine origin. Patient had an uneventful recovery and is
disease free after two years of follow-up.
Case 2
A 20-year-old man presented with a 10 × 8 cm recurrent
exophytic growth on the ventral lower aspect of the right
arm partly overlying ante cubital fossa (Figure 3). The
swelling was tender and fixed to underlying structures.
Axillary lymphadenopathy was present. The patient had
undergone excision biopsy for a nodular growth in the
same area four months earlier. An incision biopsy was
taken which was reported as sweat gland adenocarcinoma
of apocrine origin. A FNAC from the axillary lymph node
confirmed axillary metastasis from the same neoplasm.
There was no evidence of distant metastasis. Patient was
treated by wide excision and skin grafting of the primary
lesion along with axillary lymph node dissection. Histo-
logical examination of the resected specimen showed the
tumor to be PAS positive and diastase resistant confirming
the diagnosis of sweat gland adenocarcinoma of the
apocrine origin, resected margins were free and the lymph
nodes were involved (figure 4, &5). Patient was asympto-
matic for two months following which he developed local
recurrence and was taken up for re-excision. At second sur-
gery the tumor was found to infiltrate the neurovascular
bundles of the arm and humerus. In order to achieve an
R0 resection a mid arm amputation was performed and
the patient was referred for postoperative adjuvant treat-
ment. He received adjuvant chemotherapy in form of 5-
fluorouracil, and cis-platininum followed by 70 Gy of
external beam radiotherapy to the stump and 50 Gy of
radiotherapy to axilla. Patient was disease free for six
Clinical photograph showing right axillary fullness and skin  nodule Figure 1
Clinical photograph showing right axillary fullness and skin 
nodule
Clinical photograph showing recurrent sweat gland adeno- carcinoma on the arm Figure 3
Clinical photograph showing recurrent sweat gland adeno-
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months there after he developed pulmonary metastasis,
pleural effusion, and axillary recurrence. He was breath-
less, comatose and severely dehydrated thus managed by
supportive and palliative treatment and died. Unlike the
first case this patient died from disease within ten months
of the initiation of the disease process.
Discussion
Sweat gland carcinoma represent a rare group of tumors
with potential for destructive local tissue infiltration and
regional as well as distant metastasis. The management of
these neoplasms is both complex and cumbersome,
mainly due to limited availability of literature. Histologi-
Photomicrograph of sweat gland carcinoma (Hematoxyllin and eosin × 10) Figure 2
Photomicrograph of sweat gland carcinoma (Hematoxyllin and eosin × 10) Figure 2A: Showing glandular pattern with dermal 
invasion ((Hematoxyllin and eosin × 10) Figure 2B: Diastase sensitive, PAS positive tumor cells (PAS × 10)
Photomicrograph showing the tumor cells loosely infiltrating  the stroma (Hematoxylin and eosin × 10) Figure 4
Photomicrograph showing the tumor cells loosely infiltrating 
the stroma (Hematoxylin and eosin × 10)
Photomicrograph showing lymph node metastases (Hema- toxyllin and eosin × 10) Figure 5
Photomicrograph showing lymph node metastases (Hema-
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cal resemblance to the mature gland in biopsy specimen
too contributes. The diagnosis is primarily based on histo-
chemical, immunochemical, or ultrastructural features.
These tumors therefore can be considered as clinico-path-
ological dilemmas with an unpredictable biological
behavior. Rarely diagnosed clinically, they are often
encountered as operative and histological surprises [1–5].
The two basic types of sweat glands in the humans are
eccrine and apocrine. The eccrine glands are present eve-
rywhere, except the lips, glans penis, inner surface of the
prepuce, clitoris and labia minora. They are most dense
on palms and soles and respond primarily to cholinergic
stimuli, thereby playing an important role in regulating
the body temperature.
The apocrine sweat glands are limited to ear canal, the eye-
lids, the axilla, the anogenital region and the mammary
areola and are under the control of sexual hormones [2,5–
7]. The tumor was first described by Goldstein in 1982 [8]
and originates from pleuripotent adenexal cells capable of
eccrine and follicular differentiation. There is an orderly
progression of spread to regional lymph nodes and dis-
tant sites with metastatic adenocarcinomas carrying a
poor prognosis.
Division of sweat gland carcinomas into eccrine and apo-
crine groups, although desirable, is not clinically useful as
the existing literature has not adequately subdivided and
studied the separate entities well enough to make this dis-
tinction worthwhile. Sweat gland carcinomas occur pri-
marily in adult patients, with a peak incidence in fifth and
sixth decades of life [2,6,7]. Majority occur in the genital
skin and perineum (34.5%), followed by trunk (26.4%),
head and neck (18.3%) and lower extremities (13.9%)
[2,5,6,9].
The two main subtypes of sweat gland carcinomas are
apocrine gland carcinomas and eccrine carcinomas. Apo-
crine carcinomas manifest as non-tender single or multi-
ple, firm, rubbery or cystic masses with red to purple
overlying skin [2,5,9]. Microscopically they have appear-
ance of an adenocarcinoma with well-developed glandu-
lar lumina, showing characteristic evidence of
"decapitation secretion". Tumor cells are PAS positive due
to glycogen granules and diastase resistant [2]. Other fea-
tures include glandular lumen, which may be narrow or
slightly dilated with the cells of glandular and papillary
structures being large, with a strongly eosinophillic cyto-
plasm containing hemosiderin. Sudan stain for lipids may
be either negative or positive with mucin often being
present in the lumen of the glandular structures and also
around them.
Eccrine gland carcinomas posses no distinctive clinical
features making diagnosis by gross appearance virtually
impossible. They usually manifest as non-tender, subcuta-
neous nodules, primarily in elderly individuals. Individ-
ual malignant cells are rich in glycogen and stain with PAS
and are diastase sensitive with prevalent nuclear changes
and propensity for lymphatic invasion [7,9]. The glandu-
lar features show narrow lumen surrounded by a layer of
flat or cuboidal cells with no hemosiderin. PAS stain after
diastase digestion shows the tubular structures are not sur-
rounded by a basement membrane but rather by a
strongly stained cuticle containing amorphous masses in
their lumen [5,7,9–11].
Sweat Gland Carcinomas Are Broadly Divided In To 
[9,12,13]
1. Tumors bearing resemblance to their benign counter-
parts are designated accordingly
2. Those without or minimal resemblance to their benign
counterparts are further classified in to:
(A). Eccrine adenocarcinomas: These generally resemble a
moderately to poorly differentiated adenocarcinoma,
with regional variation ranging from true ductules in
some areas to infiltrative, nonglandular anaplastic cells to
glycogenated cellular zones in other areas. Contiguity
with benign eccrine structures or with overlying epidermis
is not seen.
(B) Mucinous eccrine carcinomas are characterized histo-
logically by solitary and nested anaplastic cells floating in
pools of mucin within the dermis. Thin strands of fibrous
tissue serve to compartmentalize these "lakes" of mucin.
(C) Adenoid cystic eccrine carcinomas: These are seen as
tumors of major and minor salivary glands but rarely may
be encountered as primary cutaneous tumors remote from
salivary apparatus. These tumors exhibits a population of
uniform basaloid cells forming cribriform and tubular
structures, usually with evidence of mucin and hyaline
surrounding cellular masses. Perineural invasion is preva-
lent and should be looked for specifically.
(D) Aggressive digital papillary adenoma/carcinoma:
These tumors exhibit cystic zones manifesting papillary
infoldings and lined with benign cuboidal epithelium,
more cellular zones of atypical adenomatous hyperplasia,
and areas of overt adenocarcinoma. It is questionable
whether aggressive digital papillary adenoma (ADPA) can
be distinguished histologically from aggressive digital
papillary adenocarcinoma. It is recommended that all
aggressive digital papillary (ADP) tumors be designated
and managed as "adenocarcinomas" [9,11,12]Publish with BioMed Central    and   every 
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Sites of sweat gland carcinoma metastasis include nodes,
lungs, liver and bone [2,9,13]. Metastatic deposits from
undiagnosed visceral and breast adenocarcinoma are vir-
tually indistinguishable microscopically from sweat gland
carcinoma and must be considered before a diagnosis of
metastatic sweat gland carcinoma is made. Breast cancer is
differentiated by negative PAS staining and positive estro-
gen, progesterone receptor staining.
The recommended treatment of all subtypes of sweat
gland carcinomas is wide surgical excision along with
regional lymph node dissection in the presence of clini-
cally positive nodes. Some authors advocate prophylactic
regional lymph node dissection especially in patients with
recurrent lesions after wide excision or with highly undif-
ferentiated tumors. Sweat gland carcinomas are radio
resistant and chemotherapy has been infrequently
employed [14]. Prognostic factors for sweat gland carci-
noma are difficult to identify, again owing to the small
number of reported cases. The likely prognostic factors
include size, histological type, lymph node involvement
and distant metastasis. A 10-year disease free survival rate
of 56% in the absence of lymph node metastasis is
observed which falls to 9% if nodes are involved [2,12–
14].
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